Last reviewed · How we verify

NCT05894122: MitrAlanine

Evaluation of Capillary Blood Collection Devices (Mitra® and HemaPEN®)

Status unknown Last updated 22 December 2023
What this trial tests

trial testing DM-DIV MITRA® in Phenylketonuria in 40 participants. Status unknown.

Timeline
13 December 2023
Primary endpoint
12 December 2025
12 December 2025

Quick facts

Lead sponsorUniversity Hospital, Grenoble
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment40
Start date13 December 2023
Primary completion12 December 2025
Estimated completion12 December 2025
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Grenoble

Who can join

Adults 3 Months to 18, any sex, with Phenylketonuria or Metabolic Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim is to demonstrate a new application for a blood collection device. This device is already widely used in pharmacology. It is not currently used for metabolic diseases. Its ease of use enables repeated sampling at home. What's more, the device can be sent by post, making it ideally suited to the needs of this cohort of children, whose phenylalanine levels need to be monitored very regularly.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Phenylketonuria

Currently open trials in the same condition.

Other University Hospital, Grenoble trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05894122.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing